{"transactions":[{"id":4634556,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69001,"kind":"person","name":"MacBeath Gavin","position":1,"cik":"0001738082","reported_name":"MacBeath Gavin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Voting Common Stock","published_at":"2026-10-03T00:46:55.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"25% of the restricted stock units (\"RSUs\") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement."}],"balance_after":1049767,"source":{"system":"sec-edgar","filing":"0001193125-26-412521","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526412521/ownership.xml","form_type":"4"}},{"id":4634570,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Voting Common Stock","published_at":"2026-10-03T00:45:32.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"25% of the restricted stock units (\"RSUs\") shall vest on September 30, 2028, with the remaining 75% of the RSUs vesting on the earlier of (i) reporting of completion of the pivotal trial of TSC-101, or (ii) September 30, 2030, subject to continued service with the Issuer through the applicable vesting dates and the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan and the applicable award agreement."}],"balance_after":304716,"source":{"system":"sec-edgar","filing":"0001193125-26-412518","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526412518/ownership.xml","form_type":"4"}},{"id":766655,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2026-05-22T20:08:29.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 67,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on May 20, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $0.9946 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on May 19, 2036."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 67,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on May 20, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $0.9946 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on May 19, 2036."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Biggar serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (\"the Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Biggar does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Biggar of 67,000 Stock Options on Table II. This grant of 67,000 Stock Options for Dr. Biggar is reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":67000,"derivative":{"exercise_price":0.9946,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001193125-26-236870","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526236870/ownership.xml","form_type":"4"}},{"id":766654,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2026-05-22T20:08:29.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 67,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on May 20, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $0.9946 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on May 19, 2036."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 67,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on May 20, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $0.9946 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on May 19, 2036."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Biggar serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (\"the Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Biggar does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Biggar of 67,000 Stock Options on Table II. This grant of 67,000 Stock Options for Dr. Biggar is reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":67000,"derivative":{"exercise_price":0.9946,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001193125-26-236870","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526236870/ownership.xml","form_type":"4"}},{"id":766053,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":37647,"kind":"person","name":"Woods Keith","position":1,"cik":"0001996804","reported_name":"Woods Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:05:31.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":67000,"derivative":{"exercise_price":0.9946,"expiration_date":"2036-05-20","underlying":"Voting Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001193125-26-236855","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526236855/ownership.xml","form_type":"4"}},{"id":766052,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":44751,"kind":"person","name":"Nicholson Garry A","position":1,"cik":"0001640861","reported_name":"Nicholson Garry A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:05:29.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":67000,"derivative":{"exercise_price":0.9946,"expiration_date":"2036-05-20","underlying":"Voting Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001193125-26-236854","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526236854/ownership.xml","form_type":"4"}},{"id":766187,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":37306,"kind":"person","name":"Gruia Gabriela","position":1,"cik":"0001860326","reported_name":"Gruia Gabriela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:05:21.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":67000,"derivative":{"exercise_price":0.9946,"expiration_date":"2036-05-20","underlying":"Voting Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001193125-26-236848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860326/000119312526236848/ownership.xml","form_type":"4"}},{"id":766050,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":29690,"kind":"person","name":"Dorton Katina","position":1,"cik":"0001617541","reported_name":"Dorton Katina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:05:13.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":67000,"derivative":{"exercise_price":0.9946,"expiration_date":"2036-05-20","underlying":"Voting Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001193125-26-236844","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526236844/ownership.xml","form_type":"4"}},{"id":766051,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":31402,"kind":"person","name":"Klencke Barbara","position":1,"cik":"0001647647","reported_name":"Klencke Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:05:10.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":67000,"derivative":{"exercise_price":0.9946,"expiration_date":"2036-05-20","underlying":"Voting Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001193125-26-236841","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526236841/ownership.xml","form_type":"4"}},{"id":933448,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69003,"kind":"person","name":"Amello Jason","position":1,"cik":"0001451805","reported_name":"Amello Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-22T22:52:24.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":350000,"derivative":{"exercise_price":1.12,"expiration_date":"2036-01-20","underlying":"Voting Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001193125-26-019729","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526019729/ownership.xml","form_type":"4"}},{"id":933446,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69001,"kind":"person","name":"MacBeath Gavin","position":1,"cik":"0001738082","reported_name":"MacBeath Gavin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-22T22:48:44.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":1165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":1165000,"derivative":{"exercise_price":1.12,"expiration_date":"2036-01-20","underlying":"Voting Common Stock","underlying_shares":1165000},"source":{"system":"sec-edgar","filing":"0001193125-26-019723","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526019723/ownership.xml","form_type":"4"}},{"id":933447,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69002,"kind":"person","name":"Dworak Leiden","position":1,"cik":"0001986012","reported_name":"Dworak Leiden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-22T22:30:20.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":1.12,"expiration_date":"2036-01-20","underlying":"Voting Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-019702","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526019702/ownership.xml","form_type":"4"}},{"id":933445,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69000,"kind":"person","name":"Louis Chrystal","position":1,"cik":"0002018696","reported_name":"Louis Chrystal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-22T22:27:49.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":420000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":420000,"derivative":{"exercise_price":1.12,"expiration_date":"2036-01-20","underlying":"Voting Common Stock","underlying_shares":420000},"source":{"system":"sec-edgar","filing":"0001193125-26-019697","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526019697/ownership.xml","form_type":"4"}},{"id":933444,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-22T22:19:41.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":350000,"derivative":{"exercise_price":1.12,"expiration_date":"2036-01-20","underlying":"Voting Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001193125-26-019674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312526019674/ownership.xml","form_type":"4"}},{"id":959690,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:17:28.000Z","date":"2025-12-23","kind":"purchase","planned":false,"acquired":true,"shares":6232,"price":0.8989,"value":5601.9448,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8958 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8019148,"source":{"system":"sec-edgar","filing":"0000902664-25-005396","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266425005396/ownership.xml","form_type":"4"}},{"id":959689,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:17:28.000Z","date":"2025-12-22","kind":"purchase","planned":false,"acquired":true,"shares":75500,"price":0.9,"value":67950.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8012916,"source":{"system":"sec-edgar","filing":"0000902664-25-005396","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266425005396/ownership.xml","form_type":"4"}},{"id":959688,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2025-12-23T23:17:28.000Z","date":"2025-12-19","kind":"purchase","planned":false,"acquired":true,"shares":80069,"price":0.8989,"value":71974.0241,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8862 to $0.90, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":7937416,"source":{"system":"sec-edgar","filing":"0000902664-25-005396","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266425005396/ownership.xml","form_type":"4"}},{"id":1096254,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2025-07-02T21:20:22.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 67,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 30, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $1.45 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 29, 2035."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 67,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 30, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $1.45 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 29, 2035."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Biggar serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (\"the Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Biggar does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Biggar of 67,000 Stock Options on Table II. This grant of 67,000 Stock Options for Dr. Biggar is reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":67000,"derivative":{"exercise_price":1.45,"expiration_date":"2035-06-29","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0000950170-25-093232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025093232/ownership.xml","form_type":"4"}},{"id":1096253,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2025-07-02T21:20:22.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 67,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 30, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $1.45 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 29, 2035."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 67,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 30, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $1.45 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 29, 2035."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Biggar serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (\"the Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Biggar does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Biggar of 67,000 Stock Options on Table II. This grant of 67,000 Stock Options for Dr. Biggar is reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":67000,"derivative":{"exercise_price":1.45,"expiration_date":"2035-06-29","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0000950170-25-093232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017025093232/ownership.xml","form_type":"4"}},{"id":1095333,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":31402,"kind":"person","name":"Klencke Barbara","position":1,"cik":"0001647647","reported_name":"Klencke Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:32:51.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 30, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":67000,"derivative":{"exercise_price":1.45,"expiration_date":"2035-06-30","underlying":"Voting Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0000950170-25-093058","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025093058/ownership.xml","form_type":"4"}},{"id":1095331,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":44751,"kind":"person","name":"Nicholson Garry A","position":1,"cik":"0001640861","reported_name":"Nicholson Garry A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:32:38.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 30, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":67000,"derivative":{"exercise_price":1.45,"expiration_date":"2035-06-30","underlying":"Voting Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0000950170-25-093057","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025093057/ownership.xml","form_type":"4"}},{"id":1095330,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":37647,"kind":"person","name":"Woods Keith","position":1,"cik":"0001996804","reported_name":"Woods Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:30:20.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 30, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":67000,"derivative":{"exercise_price":1.45,"expiration_date":"2035-06-30","underlying":"Voting Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0000950170-25-093047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025093047/ownership.xml","form_type":"4"}},{"id":1095329,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":29690,"kind":"person","name":"Dorton Katina","position":1,"cik":"0001617541","reported_name":"Dorton Katina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:26:55.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 30, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":67000,"derivative":{"exercise_price":1.45,"expiration_date":"2035-06-30","underlying":"Voting Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0000950170-25-093021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025093021/ownership.xml","form_type":"4"}},{"id":1095477,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":37306,"kind":"person","name":"Gruia Gabriela","position":1,"cik":"0001860326","reported_name":"Gruia Gabriela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:26:46.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 30, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":67000,"derivative":{"exercise_price":1.45,"expiration_date":"2035-06-30","underlying":"Voting Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0000950170-25-093020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860326/000095017025093020/ownership.xml","form_type":"4"}},{"id":1139073,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-21T20:49:27.000Z","date":"2025-05-20","kind":"purchase","planned":false,"acquired":true,"shares":1200000,"price":1.2,"value":1440000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":7946141,"source":{"system":"sec-edgar","filing":"0000902664-25-002511","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266425002511/ownership.xml","form_type":"4"}},{"id":1139072,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2025-05-21T20:49:27.000Z","date":"2025-05-19","kind":"purchase","planned":false,"acquired":true,"shares":1388794,"price":1.2,"value":1666552.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":6746141,"source":{"system":"sec-edgar","filing":"0000902664-25-002511","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266425002511/ownership.xml","form_type":"4"}},{"id":1274090,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T22:54:41.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 3, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer."}],"balance_after":250000,"derivative":{"exercise_price":3.065,"expiration_date":"2035-01-03","underlying":"Voting Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000950170-25-018131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025018131/ownership.xml","form_type":"4"}},{"id":1274089,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T22:54:41.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 12, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer."}],"balance_after":52500,"derivative":{"exercise_price":6,"expiration_date":"2034-01-12","underlying":"Voting Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0000950170-25-018131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025018131/ownership.xml","form_type":"4"}},{"id":1274088,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69002,"kind":"person","name":"Dworak Leiden","position":1,"cik":"0001986012","reported_name":"Dworak Leiden","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Vice President, Finance"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T22:54:39.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":46875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 12, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer."}],"balance_after":46875,"derivative":{"exercise_price":6,"expiration_date":"2034-01-12","underlying":"Voting Common Stock","underlying_shares":46875},"source":{"system":"sec-edgar","filing":"0000950170-25-018130","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025018130/ownership.xml","form_type":"4"}},{"id":1274087,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69001,"kind":"person","name":"MacBeath Gavin","position":1,"cik":"0001738082","reported_name":"MacBeath Gavin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T22:52:57.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 3, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer."}],"balance_after":800000,"derivative":{"exercise_price":3.065,"expiration_date":"2035-01-03","underlying":"Voting Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0000950170-25-018125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025018125/ownership.xml","form_type":"4"}},{"id":1274086,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69001,"kind":"person","name":"MacBeath Gavin","position":1,"cik":"0001738082","reported_name":"MacBeath Gavin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T22:52:57.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 12, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer."}],"balance_after":160000,"derivative":{"exercise_price":6,"expiration_date":"2034-01-12","underlying":"Voting Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0000950170-25-018125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025018125/ownership.xml","form_type":"4"}},{"id":1274085,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69003,"kind":"person","name":"Amello Jason","position":1,"cik":"0001451805","reported_name":"Amello Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T22:47:29.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 3, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer."}],"balance_after":270000,"derivative":{"exercise_price":3.065,"expiration_date":"2035-01-03","underlying":"Voting Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0000950170-25-018120","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025018120/ownership.xml","form_type":"4"}},{"id":1274084,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69000,"kind":"person","name":"Louis Chrystal","position":1,"cik":"0002018696","reported_name":"Louis Chrystal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T22:47:00.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 3, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer."}],"balance_after":400000,"derivative":{"exercise_price":3.065,"expiration_date":"2035-01-03","underlying":"Voting Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-25-018119","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017025018119/ownership.xml","form_type":"4"}},{"id":1320445,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant (right to buy)","published_at":"2024-12-30T21:15:18.000Z","date":"2024-12-26","kind":"purchase","planned":false,"acquired":true,"shares":7500000,"price":4,"value":30000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after December 27, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after December 27, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP and a managed account to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":7500000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":7500000},"source":{"system":"sec-edgar","filing":"0000902664-24-007064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266424007064/ownership.xml","form_type":"4"}},{"id":1330882,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-16T21:26:18.000Z","date":"2024-12-13","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":2.9014,"value":290140.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.855 to $3.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5357347,"source":{"system":"sec-edgar","filing":"0000902664-24-006934","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266424006934/ownership.xml","form_type":"4"}},{"id":1330881,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share (\"Common Stock\")","published_at":"2024-12-16T21:26:18.000Z","date":"2024-12-12","kind":"purchase","planned":false,"acquired":true,"shares":31800,"price":3.0072,"value":95628.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.99 to $3.03, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5257347,"source":{"system":"sec-edgar","filing":"0000902664-24-006934","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266424006934/ownership.xml","form_type":"4"}},{"id":1359323,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share","published_at":"2024-11-19T21:26:43.000Z","date":"2024-11-15","kind":"purchase","planned":false,"acquired":true,"shares":947,"price":4.3442,"value":4113.9574,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.335 to $4.350, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5225547,"source":{"system":"sec-edgar","filing":"0000902664-24-006718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266424006718/ownership.xml","form_type":"4"}},{"id":1400175,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":31402,"kind":"person","name":"Klencke Barbara","position":1,"cik":"0001647647","reported_name":"Klencke Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2024-09-24T21:26:24.000Z","date":"2024-09-23","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.29,"value":26450.0,"ownership":{"direct":true},"balance_after":45000,"source":{"system":"sec-edgar","filing":"0000950170-24-109133","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024109133/ownership.xml","form_type":"4"}},{"id":1421980,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":31402,"kind":"person","name":"Klencke Barbara","position":1,"cik":"0001647647","reported_name":"Klencke Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2024-08-27T22:57:46.000Z","date":"2024-08-26","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.53,"value":27650.0,"ownership":{"direct":true},"balance_after":40000,"source":{"system":"sec-edgar","filing":"0000950170-24-101166","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024101166/ownership.xml","form_type":"4"}},{"id":1421979,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":31402,"kind":"person","name":"Klencke Barbara","position":1,"cik":"0001647647","reported_name":"Klencke Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2024-08-27T22:57:46.000Z","date":"2024-08-23","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.69,"value":28450.0,"ownership":{"direct":true},"balance_after":35000,"source":{"system":"sec-edgar","filing":"0000950170-24-101166","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024101166/ownership.xml","form_type":"4"}},{"id":1421978,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-27T22:46:50.000Z","date":"2024-08-23","kind":"exercise","planned":false,"acquired":false,"shares":64166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"220,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 210,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023."}],"balance_after":365834,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-12","underlying":"Voting Common Stock","underlying_shares":64166},"source":{"system":"sec-edgar","filing":"0000950170-24-101161","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024101161/ownership.xml","form_type":"4"}},{"id":1421977,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-27T22:46:50.000Z","date":"2024-08-23","kind":"exercise","planned":false,"acquired":false,"shares":13125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter."}],"balance_after":21875,"derivative":{"exercise_price":1.81,"expiration_date":"2033-02-01","underlying":"Voting Common Stock","underlying_shares":13125},"source":{"system":"sec-edgar","filing":"0000950170-24-101161","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024101161/ownership.xml","form_type":"4"}},{"id":1421976,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-27T22:46:50.000Z","date":"2024-08-23","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter."}],"balance_after":25000,"derivative":{"exercise_price":3.27,"expiration_date":"2032-07-24","underlying":"Voting Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-101161","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024101161/ownership.xml","form_type":"4"}},{"id":1421975,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-27T22:46:50.000Z","date":"2024-08-23","kind":"exercise","planned":false,"acquired":false,"shares":54895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option vest over 4 years of service following January 18, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter."}],"balance_after":30105,"derivative":{"exercise_price":4.85,"expiration_date":"2032-01-17","underlying":"Voting Common Stock","underlying_shares":54895},"source":{"system":"sec-edgar","filing":"0000950170-24-101161","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024101161/ownership.xml","form_type":"4"}},{"id":1421974,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Voting Common Stock","published_at":"2024-08-27T22:46:50.000Z","date":"2024-08-23","kind":"sale","planned":false,"acquired":false,"shares":164686,"price":5.7814,"value":952115.6404,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.56 to $5.91, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request."}],"balance_after":4716,"source":{"system":"sec-edgar","filing":"0000950170-24-101161","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024101161/ownership.xml","form_type":"4"}},{"id":1421973,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Voting Common Stock","published_at":"2024-08-27T22:46:50.000Z","date":"2024-08-23","kind":"exercise","planned":false,"acquired":true,"shares":64166,"price":2.49,"value":159773.34,"ownership":{"direct":true},"balance_after":169402,"source":{"system":"sec-edgar","filing":"0000950170-24-101161","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024101161/ownership.xml","form_type":"4"}},{"id":1421972,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Voting Common Stock","published_at":"2024-08-27T22:46:50.000Z","date":"2024-08-23","kind":"exercise","planned":false,"acquired":true,"shares":13125,"price":1.81,"value":23756.25,"ownership":{"direct":true},"balance_after":105236,"source":{"system":"sec-edgar","filing":"0000950170-24-101161","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024101161/ownership.xml","form_type":"4"}},{"id":1421971,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Voting Common Stock","published_at":"2024-08-27T22:46:50.000Z","date":"2024-08-23","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":3.27,"value":81750.0,"ownership":{"direct":true},"balance_after":92111,"source":{"system":"sec-edgar","filing":"0000950170-24-101161","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024101161/ownership.xml","form_type":"4"}},{"id":1421970,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Voting Common Stock","published_at":"2024-08-27T22:46:50.000Z","date":"2024-08-23","kind":"exercise","planned":false,"acquired":true,"shares":54895,"price":4.85,"value":266240.75,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 7,500 shares of Voting Common Stock acquired under the TScan Therapeutics, Inc. 2021 Employee Stock Purchase Plan on December 31, 2022."}],"balance_after":67111,"source":{"system":"sec-edgar","filing":"0000950170-24-101161","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024101161/ownership.xml","form_type":"4"}},{"id":1479105,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":37647,"kind":"person","name":"Woods Keith","position":1,"cik":"0001996804","reported_name":"Woods Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:20:09.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":47500,"derivative":{"exercise_price":8.88,"expiration_date":"2034-06-11","underlying":"Voting Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0000950170-24-073696","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024073696/ownership.xml","form_type":"4"}},{"id":1479103,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":29690,"kind":"person","name":"Dorton Katina","position":1,"cik":"0001617541","reported_name":"Dorton Katina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:20:07.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":47500,"derivative":{"exercise_price":8.88,"expiration_date":"2034-06-11","underlying":"Voting Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0000950170-24-073695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024073695/ownership.xml","form_type":"4"}},{"id":1479104,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":31402,"kind":"person","name":"Klencke Barbara","position":1,"cik":"0001647647","reported_name":"Klencke Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:20:05.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":47500,"derivative":{"exercise_price":8.88,"expiration_date":"2034-06-11","underlying":"Voting Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0000950170-24-073694","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024073694/ownership.xml","form_type":"4"}},{"id":1479289,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":37306,"kind":"person","name":"Gruia Gabriela","position":1,"cik":"0001860326","reported_name":"Gruia Gabriela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:20:04.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":47500,"derivative":{"exercise_price":8.88,"expiration_date":"2034-06-11","underlying":"Voting Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0000950170-24-073693","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860326/000095017024073693/ownership.xml","form_type":"4"}},{"id":1479102,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":44751,"kind":"person","name":"Nicholson Garry A","position":1,"cik":"0001640861","reported_name":"Nicholson Garry A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:20:03.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":23750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable with respect to one-third of the shares on June 12, 2025, with the balance vesting thereafter in 24 equal monthly installments, subject to the Reporting Person's continued service at each such time."}],"balance_after":23750,"derivative":{"exercise_price":8.88,"expiration_date":"2034-06-11","underlying":"Voting Common Stock","underlying_shares":23750},"source":{"system":"sec-edgar","filing":"0000950170-24-073692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024073692/ownership.xml","form_type":"4"}},{"id":1479101,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":44751,"kind":"person","name":"Nicholson Garry A","position":1,"cik":"0001640861","reported_name":"Nicholson Garry A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:20:03.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":47500,"derivative":{"exercise_price":8.88,"expiration_date":"2034-06-11","underlying":"Voting Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0000950170-24-073692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024073692/ownership.xml","form_type":"4"}},{"id":1479648,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2024-06-14T20:13:09.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 47,500 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 12, 2024, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $8.88 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 11, 2034."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 47,500 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 12, 2024, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $8.88 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 11, 2034."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Biggar serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (\"the Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Biggar does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Biggar of 47,500 Stock Options on Table II. This grant of 47,500 Stock Options for Dr. Biggar is reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":47500,"derivative":{"exercise_price":8.88,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0000950170-24-073658","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024073658/ownership.xml","form_type":"4"}},{"id":1479647,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2024-06-14T20:13:09.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 47,500 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 12, 2024, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $8.88 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 11, 2034."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 47,500 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to Dr. Stephen R. Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 12, 2024, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $8.88 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 11, 2034."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Biggar serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (\"the Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Biggar does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Biggar of 47,500 Stock Options on Table II. This grant of 47,500 Stock Options for Dr. Biggar is reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":47500,"derivative":{"exercise_price":8.88,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0000950170-24-073658","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024073658/ownership.xml","form_type":"4"}},{"id":1528424,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69000,"kind":"person","name":"Louis Chrystal","position":1,"cik":"0002018696","reported_name":"Louis Chrystal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-03T20:05:10.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":380000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of April 22, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer."}],"balance_after":380000,"derivative":{"exercise_price":8.62,"expiration_date":"2034-04-30","underlying":"Voting Common Stock","underlying_shares":380000},"source":{"system":"sec-edgar","filing":"0000950170-24-052872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024052872/ownership.xml","form_type":"4"}},{"id":1537078,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase Common Stock","published_at":"2024-04-23T20:17:08.000Z","date":"2024-04-19","kind":"purchase","planned":false,"acquired":true,"shares":8851451,"price":7.1299,"value":63109960.4849,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") purchased 825,968 and 8,851,451 warrants to purchase common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\"), respectively, for $7.1299 per share (\"Prefunded Warrants\") pursuant to an underwritten offering that closed on April 19, 2024. The Prefunded Warrants have no expiration date\nand are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as\namended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") purchased 825,968 and 8,851,451 warrants to purchase common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\"), respectively, for $7.1299 per share (\"Prefunded Warrants\") pursuant to an underwritten offering that closed on April 19, 2024. The Prefunded Warrants have no expiration date\nand are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as\namended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") purchased 825,968 and 8,851,451 warrants to purchase common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\"), respectively, for $7.1299 per share (\"Prefunded Warrants\") pursuant to an underwritten offering that closed on April 19, 2024. The Prefunded Warrants have no expiration date\nand are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as\namended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") purchased 825,968 and 8,851,451 warrants to purchase common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\"), respectively, for $7.1299 per share (\"Prefunded Warrants\") pursuant to an underwritten offering that closed on April 19, 2024. The Prefunded Warrants have no expiration date\nand are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as\namended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":43158741,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":8851451},"source":{"system":"sec-edgar","filing":"0000950170-24-046916","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024046916/ownership.xml","form_type":"4"}},{"id":1537077,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase Common Stock","published_at":"2024-04-23T20:17:08.000Z","date":"2024-04-19","kind":"purchase","planned":false,"acquired":true,"shares":825968,"price":7.1299,"value":5889069.2432,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") purchased 825,968 and 8,851,451 warrants to purchase common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\"), respectively, for $7.1299 per share (\"Prefunded Warrants\") pursuant to an underwritten offering that closed on April 19, 2024. The Prefunded Warrants have no expiration date\nand are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as\namended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") purchased 825,968 and 8,851,451 warrants to purchase common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\"), respectively, for $7.1299 per share (\"Prefunded Warrants\") pursuant to an underwritten offering that closed on April 19, 2024. The Prefunded Warrants have no expiration date\nand are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as\namended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") purchased 825,968 and 8,851,451 warrants to purchase common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\"), respectively, for $7.1299 per share (\"Prefunded Warrants\") pursuant to an underwritten offering that closed on April 19, 2024. The Prefunded Warrants have no expiration date\nand are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as\namended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") purchased 825,968 and 8,851,451 warrants to purchase common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\"), respectively, for $7.1299 per share (\"Prefunded Warrants\") pursuant to an underwritten offering that closed on April 19, 2024. The Prefunded Warrants have no expiration date\nand are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as\namended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":4018678,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":825968},"source":{"system":"sec-edgar","filing":"0000950170-24-046916","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000095017024046916/ownership.xml","form_type":"4"}},{"id":1536909,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant (right to buy)","published_at":"2024-04-23T20:15:31.000Z","date":"2024-04-19","kind":"purchase","planned":false,"acquired":true,"shares":5000000,"price":7.1299,"value":35649500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after April 19, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 4.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after April 19, 2024, exercise the Pre-funded Warrant until it has been exercised in full. The Pre-funded Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Pre-Funded Warrants until such time as the holder, together with the Reporting Persons and certain other related parties, would not beneficially own after any such exercise more than 4.99% of the then issued and outstanding Common Stock (the \"Blocker\"). Due to the Blocker, the Pre-funded Warrants beneficially owned by the Reporting Persons are not presently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5000000,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0000902664-24-003030","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266424003030/ownership.xml","form_type":"4"}},{"id":1661954,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69003,"kind":"person","name":"Amello Jason","position":1,"cik":"0001451805","reported_name":"Amello Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-02T21:21:56.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 29, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer."}],"balance_after":750000,"derivative":{"exercise_price":5.15,"expiration_date":"2034-01-31","underlying":"Voting Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0000950170-24-010522","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024010522/ownership.xml","form_type":"4"}},{"id":1702559,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":95963,"kind":"person","name":"BARBERICH TIMOTHY J","position":1,"cik":"0001120355","reported_name":"BARBERICH TIMOTHY J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-12-21T17:00:47.000Z","date":"2023-12-19","kind":"purchase","planned":false,"acquired":true,"shares":317,"price":4.9685,"value":1575.0145,"ownership":{"direct":true},"balance_after":67027,"source":{"system":"sec-edgar","filing":"0000950170-23-072291","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1120355/000095017023072291/ownership.xml","form_type":"4"}},{"id":1702558,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":95963,"kind":"person","name":"BARBERICH TIMOTHY J","position":1,"cik":"0001120355","reported_name":"BARBERICH TIMOTHY J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-12-21T17:00:47.000Z","date":"2023-12-18","kind":"purchase","planned":false,"acquired":true,"shares":28830,"price":4.8866,"value":140880.678,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $4.63 to $5.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":66710,"source":{"system":"sec-edgar","filing":"0000950170-23-072291","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120355/000095017023072291/ownership.xml","form_type":"4"}},{"id":1707379,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":31402,"kind":"person","name":"Klencke Barbara","position":1,"cik":"0001647647","reported_name":"Klencke Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-12-18T23:01:18.000Z","date":"2023-12-14","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.08,"value":25400.0,"ownership":{"direct":true},"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000950170-23-071208","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023071208/ownership.xml","form_type":"4"}},{"id":1717988,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":37647,"kind":"person","name":"Woods Keith","position":1,"cik":"0001996804","reported_name":"Woods Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T13:20:03.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) December 6, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":17500,"derivative":{"exercise_price":6.74,"expiration_date":"2033-12-05","underlying":"Voting Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-23-068925","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023068925/ownership.xml","form_type":"4"}},{"id":1824191,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69002,"kind":"person","name":"Dworak Leiden","position":1,"cik":"0001986012","reported_name":"Dworak Leiden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-24T23:39:09.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of July 21, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":2.23,"expiration_date":"2033-07-20","underlying":"Voting Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-23-034156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023034156/ownership.xml","form_type":"4"}},{"id":1854480,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":29690,"kind":"person","name":"Dorton Katina","position":1,"cik":"0001617541","reported_name":"Dorton Katina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T22:17:08.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":35000,"derivative":{"exercise_price":2.66,"expiration_date":"2033-06-12","underlying":"Voting Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-23-015642","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924323015642/doc4.xml","form_type":"4"}},{"id":1854614,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":37306,"kind":"person","name":"Gruia Gabriela","position":1,"cik":"0001860326","reported_name":"Gruia Gabriela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T22:14:27.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":35000,"derivative":{"exercise_price":2.66,"expiration_date":"2033-06-12","underlying":"Voting Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-23-015640","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860326/000089924323015640/doc4.xml","form_type":"4"}},{"id":1854479,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":31402,"kind":"person","name":"Klencke Barbara","position":1,"cik":"0001647647","reported_name":"Klencke Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T22:13:36.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":36524,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"35,000 shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2024 and (ii) the next annual meeting of the Issuer's stockholders, with 1,524 shares subject to this option vesting and becoming exercisable in full on June 13, 2023, in each case subject to the Reporting Person's continued service at such time."}],"balance_after":36524,"derivative":{"exercise_price":2.66,"expiration_date":"2033-06-12","underlying":"Voting Common Stock","underlying_shares":36524},"source":{"system":"sec-edgar","filing":"0000899243-23-015639","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924323015639/doc4.xml","form_type":"4"}},{"id":1854478,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69001,"kind":"person","name":"MacBeath Gavin","position":1,"cik":"0001738082","reported_name":"MacBeath Gavin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T22:08:34.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":1121300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"536,300 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 585,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023."}],"balance_after":1121300,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-12","underlying":"Voting Common Stock","underlying_shares":1121300},"source":{"system":"sec-edgar","filing":"0000899243-23-015635","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924323015635/doc4.xml","form_type":"4"}},{"id":1854477,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T22:01:48.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":430000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"220,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 210,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023."}],"balance_after":430000,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-12","underlying":"Voting Common Stock","underlying_shares":430000},"source":{"system":"sec-edgar","filing":"0000899243-23-015632","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924323015632/doc4.xml","form_type":"4"}},{"id":1854875,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2023-06-15T20:40:00.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 35,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\")\ngranted by the Issuer to Dr. Stephen Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\") on June 13, 2023, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $2.66 and vest in full upon the earlier of the first anniversary of the grant date or the Issuer's 2024 annual meeting subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\"). The Stock Options expire on June 13, 2033. Dr. Biggar serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\") and their affiliates."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 35,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\")\ngranted by the Issuer to Dr. Stephen Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\") on June 13, 2023, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $2.66 and vest in full upon the earlier of the first anniversary of the grant date or the Issuer's 2024 annual meeting subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\"). The Stock Options expire on June 13, 2033. Dr. Biggar serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\") and their affiliates."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Includes 35,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\")\ngranted by the Issuer to Dr. Stephen Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\") on June 13, 2023, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $2.66 and vest in full upon the earlier of the first anniversary of the grant date or the Issuer's 2024 annual meeting subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\"). The Stock Options expire on June 13, 2033. Dr. Biggar serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\") and their affiliates."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, Dr. Biggar does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options and any Common Stock acquired upon the exercise of Stock Options (i.e. no direct pecuniary interest)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Pursuant to agreements between Dr. Biggar and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock acquired as a result of the exercise of the Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Biggar of 35,000 Stock Options on Table II. This grant of 35,000 Stock Options for Dr. Biggar is reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds of for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for\nthe benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":35000,"derivative":{"exercise_price":2.66,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-23-037371","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123037371/doc4.xml","form_type":"4"}},{"id":1854874,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2023-06-15T20:40:00.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 35,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\")\ngranted by the Issuer to Dr. Stephen Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\") on June 13, 2023, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $2.66 and vest in full upon the earlier of the first anniversary of the grant date or the Issuer's 2024 annual meeting subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\"). The Stock Options expire on June 13, 2033. Dr. Biggar serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\") and their affiliates."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 35,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\")\ngranted by the Issuer to Dr. Stephen Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\") on June 13, 2023, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $2.66 and vest in full upon the earlier of the first anniversary of the grant date or the Issuer's 2024 annual meeting subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\"). The Stock Options expire on June 13, 2033. Dr. Biggar serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\") and their affiliates."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Includes 35,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\")\ngranted by the Issuer to Dr. Stephen Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\") on June 13, 2023, in his capacity as a director of the Issuer, pursuant to the Issuer's Amended 2021 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $2.66 and vest in full upon the earlier of the first anniversary of the grant date or the Issuer's 2024 annual meeting subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\"). The Stock Options expire on June 13, 2033. Dr. Biggar serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\") and their affiliates."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian\nC. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held\nfor the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole\ngeneral partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a\nportion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, Dr. Biggar does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options and any Common Stock acquired upon the exercise of Stock Options (i.e. no direct pecuniary interest)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Pursuant to agreements between Dr. Biggar and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock acquired as a result of the exercise of the Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Biggar of 35,000 Stock Options on Table II. This grant of 35,000 Stock Options for Dr. Biggar is reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds of for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for\nthe benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":35000,"derivative":{"exercise_price":2.66,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-23-037371","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123037371/doc4.xml","form_type":"4"}},{"id":1854747,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":95963,"kind":"person","name":"BARBERICH TIMOTHY J","position":1,"cik":"0001120355","reported_name":"BARBERICH TIMOTHY J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T18:25:52.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":35000,"derivative":{"exercise_price":2.66,"expiration_date":"2033-06-12","underlying":"Voting Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-23-015646","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120355/000089924323015646/doc4.xml","form_type":"4"}},{"id":1854689,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":112288,"kind":"person","name":"Barton Debora","position":1,"cik":"0001936730","reported_name":"Barton Debora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T18:19:57.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":430000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"220,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares  on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 210,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023."}],"balance_after":430000,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-12","underlying":"Voting Common Stock","underlying_shares":430000},"source":{"system":"sec-edgar","filing":"0000899243-23-015644","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936730/000089924323015644/doc4.xml","form_type":"4"}},{"id":1854627,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":112286,"kind":"person","name":"Silver Brian M.","position":1,"cik":"0001860597","reported_name":"Silver Brian M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T18:09:43.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":632500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"302,500 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 330,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023."}],"balance_after":632500,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-12","underlying":"Voting Common Stock","underlying_shares":632500},"source":{"system":"sec-edgar","filing":"0000899243-23-015636","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860597/000089924323015636/doc4.xml","form_type":"4"}},{"id":1865511,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":95963,"kind":"person","name":"BARBERICH TIMOTHY J","position":1,"cik":"0001120355","reported_name":"BARBERICH TIMOTHY J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-06-06T19:53:38.000Z","date":"2023-06-02","kind":"purchase","planned":false,"acquired":true,"shares":37880,"price":2.6284,"value":99563.792,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $2.60 to $2.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person's prior reports inadvertently included 33,259 shares of the Issuer's Voting Common Stock held by the Barberich Family Trust as directly owned by the Reporting Person. These shares are held in a trust for the benefit of the Reporting Person's children. The Reporting Person's spouse is the grantor of the trust and retains certain rights to remove and replace the trustee of the trust. The Reporting Person disclaims beneficial ownership of these shares."}],"balance_after":37880,"source":{"system":"sec-edgar","filing":"0000899243-23-014618","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1120355/000089924323014618/doc4.xml","form_type":"4"}},{"id":1870130,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T21:35:20.000Z","date":"2023-05-31","kind":"sale","planned":false,"acquired":false,"shares":400,"price":2.5075,"value":1003.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of ection 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5224600,"source":{"system":"sec-edgar","filing":"0000902664-23-003407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266423003407/ownership.xml","form_type":"4"}},{"id":1870129,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T21:35:20.000Z","date":"2023-05-31","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":2.5201,"value":37801.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of ection 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5225000,"source":{"system":"sec-edgar","filing":"0000902664-23-003407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266423003407/ownership.xml","form_type":"4"}},{"id":1870128,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.0001 par value per share Common Stock","published_at":"2023-06-02T21:35:20.000Z","date":"2023-05-31","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":2.5148,"value":25148.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of ection 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5240000,"source":{"system":"sec-edgar","filing":"0000902664-23-003407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000090266423003407/ownership.xml","form_type":"4"}},{"id":1870742,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase Common Stock","published_at":"2023-06-02T20:00:34.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":34307290,"price":1.9999,"value":68611149.271,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") purchased 3,192,710 and 34,307,290 warrants to purchase common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\"), respectively, for $1.9999 per share (\"Prefunded Warrants\") pursuant to an underwritten offering that closed for the Commmon Stock on May 31, 2023 and for the Prefunded Warrants on June 1, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") purchased 3,192,710 and 34,307,290 warrants to purchase common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\"), respectively, for $1.9999 per share (\"Prefunded Warrants\") pursuant to an underwritten offering that closed for the Commmon Stock on May 31, 2023 and for the Prefunded Warrants on June 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and\n(ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the securities reported in column 7\nof Table II beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital,\nL.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life\nSciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":34307290,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":34307290},"source":{"system":"sec-edgar","filing":"0001209191-23-033647","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123033647/doc4.xml","form_type":"4"}},{"id":1870741,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase Common Stock","published_at":"2023-06-02T20:00:34.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":3192710,"price":1.9999,"value":6385100.729,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") purchased 3,192,710 and 34,307,290 warrants to purchase common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\"), respectively, for $1.9999 per share (\"Prefunded Warrants\") pursuant to an underwritten offering that closed for the Commmon Stock on May 31, 2023 and for the Prefunded Warrants on June 1, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\") purchased 3,192,710 and 34,307,290 warrants to purchase common stock (\"Common Stock\") of TScan Therapeutics, Inc. (the \"Issuer\"), respectively, for $1.9999 per share (\"Prefunded Warrants\") pursuant to an underwritten offering that closed for the Commmon Stock on May 31, 2023 and for the Prefunded Warrants on June 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis without consideration into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian\nC. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 7 of Table II directly\nheld by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general\npartner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion\nof the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds."}],"balance_after":3192710,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":3192710},"source":{"system":"sec-edgar","filing":"0001209191-23-033647","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123033647/doc4.xml","form_type":"4"}},{"id":1922306,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":31402,"kind":"person","name":"Klencke Barbara","position":1,"cik":"0001647647","reported_name":"Klencke Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-10T14:39:45.000Z","date":"2023-04-06","kind":"grant","planned":false,"acquired":true,"shares":9146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in thirty-six equal monthly installments following April 6, 2023, subject to the Reporting Person's continued service at such time."}],"balance_after":9146,"derivative":{"exercise_price":2.2,"expiration_date":"2033-04-05","underlying":"Voting Common Stock","underlying_shares":9146},"source":{"system":"sec-edgar","filing":"0000899243-23-010999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924323010999/doc4.xml","form_type":"4"}},{"id":2030677,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":26195,"kind":"person","name":"SOUTHWELL DAVID P","position":1,"cik":"0001251553","reported_name":"SOUTHWELL DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-06T22:18:26.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter."}],"balance_after":100000,"derivative":{"exercise_price":1.81,"expiration_date":"2033-02-01","underlying":"Voting Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-23-004063","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924323004063/doc4.xml","form_type":"4"}},{"id":2030676,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69001,"kind":"person","name":"MacBeath Gavin","position":1,"cik":"0001738082","reported_name":"MacBeath Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-06T22:16:55.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter."}],"balance_after":40000,"derivative":{"exercise_price":1.81,"expiration_date":"2033-02-01","underlying":"Voting Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-23-004062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924323004062/doc4.xml","form_type":"4"}},{"id":2030675,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-06T22:15:50.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter."}],"balance_after":35000,"derivative":{"exercise_price":1.81,"expiration_date":"2033-02-01","underlying":"Voting Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-23-004064","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924323004064/doc4.xml","form_type":"4"}},{"id":2030931,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":112288,"kind":"person","name":"Barton Debora","position":1,"cik":"0001936730","reported_name":"Barton Debora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-06T17:14:24.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter."}],"balance_after":50000,"derivative":{"exercise_price":1.81,"expiration_date":"2033-02-01","underlying":"Voting Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-23-004061","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936730/000089924323004061/doc4.xml","form_type":"4"}},{"id":2075046,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":112286,"kind":"person","name":"Silver Brian M.","position":1,"cik":"0001860597","reported_name":"Silver Brian M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Voting Common Stock","published_at":"2022-12-29T14:34:48.000Z","date":"2022-12-28","kind":"purchase","acquired":true,"shares":3158,"price":1.5646,"value":4941.0068,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $1.55 to $1.57, inclusive."}],"balance_after":32885,"source":{"system":"sec-edgar","filing":"0000899243-22-039506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860597/000089924322039506/doc4.xml","form_type":"4"}},{"id":2075045,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":112286,"kind":"person","name":"Silver Brian M.","position":1,"cik":"0001860597","reported_name":"Silver Brian M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Voting Common Stock","published_at":"2022-12-29T14:34:48.000Z","date":"2022-12-27","kind":"purchase","acquired":true,"shares":2842,"price":1.5047,"value":4276.3574,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $1.46 to $1.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."}],"balance_after":29727,"source":{"system":"sec-edgar","filing":"0000899243-22-039506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860597/000089924322039506/doc4.xml","form_type":"4"}},{"id":2201372,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":26195,"kind":"person","name":"SOUTHWELL DAVID P","position":1,"cik":"0001251553","reported_name":"SOUTHWELL DAVID P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-27T20:30:58.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter."}],"balance_after":100000,"derivative":{"exercise_price":3.27,"expiration_date":"2032-07-24","underlying":"Voting Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-22-026849","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924322026849/doc4.xml","form_type":"4"}},{"id":2201375,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":68999,"kind":"person","name":"ZDRAVESKI ZORAN","position":1,"cik":"0001741285","reported_name":"ZDRAVESKI ZORAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-27T20:30:37.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter."}],"balance_after":50000,"derivative":{"exercise_price":3.27,"expiration_date":"2032-07-24","underlying":"Voting Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-22-026847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924322026847/doc4.xml","form_type":"4"}},{"id":2201371,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":69001,"kind":"person","name":"MacBeath Gavin","position":1,"cik":"0001738082","reported_name":"MacBeath Gavin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-27T20:30:25.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter."}],"balance_after":100000,"derivative":{"exercise_price":3.27,"expiration_date":"2032-07-24","underlying":"Voting Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-22-026844","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924322026844/doc4.xml","form_type":"4"}},{"id":2201399,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":125108,"kind":"person","name":"Desmarais William","position":1,"cik":"0001860207","reported_name":"Desmarais William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-27T16:30:53.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter."}],"balance_after":30000,"derivative":{"exercise_price":3.27,"expiration_date":"2032-07-24","underlying":"Voting Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-026848","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860207/000089924322026848/doc4.xml","form_type":"4"}},{"id":2201405,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":112286,"kind":"person","name":"Silver Brian M.","position":1,"cik":"0001860597","reported_name":"Silver Brian M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-27T16:30:37.000Z","date":"2022-07-25","kind":"grant","acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter."}],"balance_after":220000,"derivative":{"exercise_price":3.27,"expiration_date":"2032-07-24","underlying":"Voting Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0000899243-22-026846","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860597/000089924322026846/doc4.xml","form_type":"4"}},{"id":2210883,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":112288,"kind":"person","name":"Barton Debora","position":1,"cik":"0001936730","reported_name":"Barton Debora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-07T07:57:10.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest with respect to 25% of the shares after 12 months of continuous service to the Issuer following July 5, 2022, and the balance will vest in equal monthly installments over the next 36 months of continuous service to the Issuer."}],"balance_after":150000,"derivative":{"exercise_price":3.17,"expiration_date":"2032-07-04","underlying":"Voting Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-22-025626","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936730/000089924322025626/doc4.xml","form_type":"4"}},{"id":2245774,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2022-06-03T20:40:22.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":9146,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"9,146 non-qualified stock options (\"Stock Options\") exercisable solely into common stock of TScan Therapeutics, Inc. (the \"Issuer\") were\ngranted under the Issuer's 2021 Equity Incentive Plan to Dr. Stephen Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\") in his\ncapacity as a director of the Issuer. The Stock Options with a strike price of $3.17 vest in full upon the earlier of the first anniversary of the grant date or the Issuer's 2023 annual meeting, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\"). The Stock Options expire on May 31, 2032. Dr. Biggar serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"9,146 non-qualified stock options (\"Stock Options\") exercisable solely into common stock of TScan Therapeutics, Inc. (the \"Issuer\") were\ngranted under the Issuer's 2021 Equity Incentive Plan to Dr. Stephen Biggar, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\") in his\ncapacity as a director of the Issuer. The Stock Options with a strike price of $3.17 vest in full upon the earlier of the first anniversary of the grant date or the Issuer's 2023 annual meeting, subject to Dr. Biggar's continued service on the board of directors of the Issuer (the \"Board\"). The Stock Options expire on May 31, 2032. Dr. Biggar serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The policies of the Funds and the Adviser do not permit full-time employees of the Adviser or managing members of the Adviser GP (as defined below) to receive compensation for serving as a director of the Issuer. The Funds are entitled to receive all of the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options (i.e. no direct pecuniary interest)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of\nthe securities held by the Funds. The Adviser has investment and dispositive power over the Stock Options and any common stock of the Issuer received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":9146,"derivative":{"exercise_price":3.17,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":9146},"source":{"system":"sec-edgar","filing":"0001209191-22-034093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919122034093/doc4.xml","form_type":"4"}},{"id":2244966,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":29690,"kind":"person","name":"Dorton Katina","position":1,"cik":"0001617541","reported_name":"Dorton Katina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T20:30:46.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":9146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 1, 2023 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":9146,"derivative":{"exercise_price":3.17,"expiration_date":"2032-05-31","underlying":"Voting Common Stock","underlying_shares":9146},"source":{"system":"sec-edgar","filing":"0000899243-22-020963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924322020963/doc4.xml","form_type":"4"}},{"id":2245151,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":37306,"kind":"person","name":"Gruia Gabriela","position":1,"cik":"0001860326","reported_name":"Gruia Gabriela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T20:30:34.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":9146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 1, 2023 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":9146,"derivative":{"exercise_price":3.17,"expiration_date":"2032-05-31","underlying":"Voting Common Stock","underlying_shares":9146},"source":{"system":"sec-edgar","filing":"0000899243-22-020965","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860326/000089924322020965/doc4.xml","form_type":"4"}},{"id":2244965,"issuer":{"id":7255,"kind":"organization","name":"TScan Therapeutics, Inc."},"owners":[{"id":126566,"kind":"person","name":"Harel Ittai","position":1,"cik":"0001632710","reported_name":"Harel Ittai","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T20:30:20.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":9146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 1, 2023 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":9146,"derivative":{"exercise_price":3.17,"expiration_date":"2032-05-31","underlying":"Voting Common Stock","underlying_shares":9146},"source":{"system":"sec-edgar","filing":"0000899243-22-020961","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1783328/000089924322020961/doc4.xml","form_type":"4"}}],"next_cursor":"2022-06-03T20:30:20.000000Z,2244965"}